Health Care & Life Sciences » Biotechnology | Macrogenics Inc.

Macrogenics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
58,034.70
47,797.00
100,854.00
91,880.00
157,742.00
60,121
SG&A Expense
56,475.30
84,290.00
117,836.00
144,314.00
172,657.00
222,127
EBIT
366.00
38,315.00
20,182.00
60,042.00
22,143.00
171,206
Unusual Expense
626.30
-
-
-
-
-
Non Operating Income/Expense
0.50
2.00
42.00
1,514.00
2,517.00
2,547
Pretax Income
260.80
38,313.00
20,140.00
58,528.00
19,626.00
171,453
Consolidated Net Income
260.80
38,313.00
20,140.00
58,528.00
19,626.00
171,453
Net Income
260.80
38,313.00
20,140.00
58,528.00
19,626.00
171,453
Net Income After Extraordinaries
260.80
38,313.00
20,140.00
58,528.00
19,626.00
171,453
Net Income Available to Common
260.80
38,313.00
20,140.00
58,528.00
19,626.00
171,453
EPS (Basic)
0.04
1.40
0.63
1.69
0.54
4.19
Basic Shares Outstanding
26,989.00
27,385.00
31,801.60
34,685.30
36,095.10
40,925.30
EPS (Diluted)
0.01
1.40
0.63
1.69
0.54
4.19
Diluted Shares Outstanding
26,989.00
27,385.00
31,801.60
34,685.30
36,095.10
40,925.30
EBITDA
1,559.30
36,493.00
16,982.00
52,434.00
14,915.00
162,006

About Macrogenics

View Profile
Address
9740 Medical Center Drive
Rockville Maryland 20850
United States
Employees -
Website http://www.macrogenics.com
Updated 07/08/2019
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its portfolio includes Margetuximab, Flotetuzumab, MGA012, MGD013, Enoblituzumab, MGD009, and Teplizumab. The company was founded by Scott E.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.